The Sarcoma Comprehensive NGS Fusion Panel is an RNA-based next-generation sequencing panel that detects translocations and fusions with known and novel fusion partners of these genes: ACTB, AHRR, ALK, ASPSCR1, ATF1, ATIC, BCOR, BRAF, C11orf95, CAMTA1, CARS1, CCNB3, CDH11, CIC, CLTC, CNBP, COL1A1, COL1A2, CREB1, CREB3L1, CREB3L2, CSF1, CTNNB1, DDIT3, DUX4, EML4, EPC1, ERG, ETV1, ETV4, ETV6, EWSR1, FEV, FLI1, FOXO1, FRK, FUS, GLI1, HAS2, HEY1, HMGA2, IL2RB, ITK, JAZF1, LMNA, LPP, MEAF6, MRTFB, MYH9, MYLK, NAB2, NCOA1, NCOA2, NFATC2, NFIB, NR4A3, NTRK1, NTRK2, NTRK3, NUTM2A, NUTM2B, OMD, PAX3, PATZ1, PAX7, PBX1, PDGFB, PDGFRB, PHF1, PLAG1, POU5F1, RAD51B, RANBP2, ROS1, SEC31A, SRF, SS18, SSX1, SSX2, SSX4B, STAT6, SUZ12, SYK, TAF15, TCF12, TEAD1, TFE3, TFG, THRAP3, TPM3, TPM4, USP6, WT1, WWTR1, YAP1, YWHAE and ZNF444.
Sarcoma is a connective tissue cancer of mesenchymal origin which accounts for more than 20% of pediatric solid tumor malignancies but is rare in adults. The majority of sarcomas are classified as soft tissue sarcomas and approximately 10% are malignant bone tumors. Genomic rearrangements called translocations are present in approximately 20-30% of sarcomas and are associated with different subtypes of sarcomas. Identification of translocations can be useful for diagnosis, disease subclassification, and determining therapy. Compared to FISH, molecular detection of sarcoma translocations, as provided in this test, requires less tumor sample for a much broader and therefore more cost-effective screen.
- FFPE tissue: Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
Use cold pack for transporting block during summer to prevent block from melting. Slides can be packed at room temperature.